Keros Therapeutics (NASDAQ:KROS) Issues Earnings Results

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22, Zacks reports. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics Stock Up 0.3 %

Shares of NASDAQ:KROS traded up $0.03 during midday trading on Wednesday, hitting $10.94. 1,257,944 shares of the stock traded hands, compared to its average volume of 1,614,620. The business’s 50 day moving average is $12.88 and its two-hundred day moving average is $40.20. The stock has a market capitalization of $443.15 million, a PE ratio of -2.10 and a beta of 1.39. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00.

Analysts Set New Price Targets

Several brokerages recently issued reports on KROS. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Oppenheimer cut their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday, January 16th. Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $47.00 to $15.00 in a research report on Friday, January 17th. Finally, BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.